ASN-002

BIOLOGICAL3 trials

Sponsors

Ascend Biopharmaceuticals Ltd

Conditions

Basal Cell CarcinomaBasal Cell Carcinoma in Basal Cell Nevus SyndromeBasal Cell Nevus SyndromeNodular Basal Cell Carcinoma of SkinSkin Neoplasm

Phase 1

A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma

CompletedNCT02550678

Ascend Biopharmaceuticals LtdBasal Cell Nevus Syndrome, Nodular Basal Cell Carcinoma of Skin, Skin Neoplasm

Start: 2015-09-30End: 2017-11-30Updated: 2018-06-06

Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)

SuspendedNCT03208296

Ascend Biopharmaceuticals LtdBasal Cell Carcinoma in Basal Cell Nevus Syndrome

Start: 2017-12-01End: 2025-03-31Target: 24Updated: 2023-02-06

Phase 2

Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor

CompletedNCT04416516

Ascend Biopharmaceuticals LtdBasal Cell Carcinoma, Basal Cell Nevus Syndrome

Start: 2020-07-16End: 2024-02-14Updated: 2024-04-10

Related Papers

Evaluation of adnexal features and histological response to intralesional SP-002 in nodular basal cell carcinoma.

Journal of Clinical Oncology2026-05-27